iTAP/FRMD8 is required for ADAM17-mediated functions in inflammatory diseases

  • Marina Badenes I-MVET (Research in Veterinary Medicine), Faculty of Veterinary Medicine, Lusófona University - Lisbon University Center, Lisbon, Portugal
  • Emma Burbridge GIMM (Gulbenkian Institute for Molecular Medicine), Portugal
  • Ioanna Oikonomidi GIMM (Gulbenkian Institute for Molecular Medicine), Portugal
  • Érika de Carvalho GIMM (Gulbenkian Institute for Molecular Medicine), Portugal
  • Abdulbasit Amin GIMM (Gulbenkian Institute for Molecular Medicine), Portugal
  • Pedro Faísca I-MVET (Research in Veterinary Medicine), Faculty of Veterinary Medicine, Lusófona University - Lisbon University Center, Lisbon, Portugal
  • Pedro M. Domingos ITQB (Instituto de Tecnologia Química e Biológica António Xavier), Universidade Nova de Lisboa, Oeiras, Portugal
  • Colin Adrain GIMM (Gulbenkian Institute for Molecular Medicine), Portugal

Resumo

Introduction: The metalloprotease ADAM17 (also called TACE) plays fundamental roles during development and promotes homeostasis and multiple inflammatory diseases by shedding key signalling molecules from the cell surface. ADAM17 exists within an assemblage, the "sheddase complex," containing a rhomboid pseudoprotease (iRhom1 or iRhom2). The FERM domain-containing protein iTAP/Frmd8 is an iRhom-binding protein that prevents the precocious shunting of ADAM17 and iRhom2 to lysosomes and their consequent degradation. 

 

Objectives: The purpose of this study was to determine the impact of iTAP/Frmd8 loss on inflammatory Adam17-associated phenotypes in mice. 

 

Materials and Methods: We challenged controls versus iTAP/Frmd8 global KO to inflammatory models of disease associated to ADAM17 pathway, specifically sepsis and colitis. We also performed studies on mouse iTAP/Frmd8 global KO derived inflammatory cells.

 

Results: We found that iTAP/Frmd8 KO mice exhibit defects in inflammatory and intestinal epithelial barrier repair functions associated with Adam17 loss, but not the collateral defects associated to ADAM17 deletion.

Conclusions: This works shows that pharmacological intervention at the level of iTAP/Frmd8 may be beneficial to target ADAM17 activity to treat chronic inflammatory diseases.

 

Funding: This work was supported by Fundação para a Ciência e Tecnologia (FCT) (grant LISBOA-01–0145-FEDER-031330).


Keywords: iTAP/Frmd8, ADAM17, inflammation, sepsis, colitis.

Downloads

Não há dados estatísticos.
Publicado
2026-02-20